SEC Form 4 · accession 0001209191-18-003981
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey M Leiden
Officer — CEO & President · Director
Period of report
Jan 16, 2018
Accepted (ET)
Jan 17, 2018 · 4:45 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 16, 2018 | M | 44,250 | $48.74 | A | 176,747 | D | |
| Common Stock | Jan 16, 2018 | M | 55,313 | $45.11 | A | 232,060 | D | |
| Common StockF2,F3 | Jan 16, 2018 | S | 42,371 | $155.77 | D | 189,689 | D | |
| Common StockF3,F4 | Jan 16, 2018 | S | 19,808 | $156.62 | D | 169,881 | D | |
| Common StockF3,F5 | Jan 16, 2018 | S | 11,471 | $157.67 | D | 158,410 | D | |
| Common StockF3,F6 | Jan 16, 2018 | S | 17,918 | $158.79 | D | 140,492 | D | |
| Common StockF3,F7 | Jan 16, 2018 | S | 7,995 | $159.39 | D | 132,497 | D | |
| Common Stock | holding | — | — | — | 440 | I | 401(k) |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F8 | $48.74 | Jan 16, 2018 | M | 44,250 | D | — | Jul 24, 2022 | Common Stock | 44,250 | 0 | D |
| Stock Option (Right to Buy)F8 | $45.11 | Jan 16, 2018 | M | 55,313 | D | — | Feb 4, 2023 | Common Stock | 55,313 | 0 | D |
Explanation of responses
- F1Transaction made pursuant to Dr. Leiden's company-approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $155.77 (range $155.18 to $156.17).
- F3Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $156.62 (range $156.18 to $157.17).
- F5Open market sales reported on this line occurred at a weighted average price of $157.67 (range $157.18 to $158.17).
- F6Open market sales reported on this line occurred at a weighted average price of $158.79 (range $158.18 to $159.16).
- F7Open market sales reported on this line occurred at a weighted average price of $159.39 (range $159.18 to $159.75).
- F8Fully vested.